Vaccination to prevent vulvar cancer due to human papillomavirus

This indication refers to primary immunoprophylaxis against malignant neoplasms of the vulva initiated by high-risk oncogenic types of human papillomavirus (primarily HPV types 16 and 18) Pathophysiologically, persistent mucosal infection with oncogenic HPV promotes cellular transformation through viral oncoproteins that inactivate host tumor suppressor proteins, driving progression from high-grade squamous intraepithelial lesions (vulvar intraepithelial neoplasia) to invasive squamous cell carc...

This indication refers to primary immunoprophylaxis against malignant neoplasms of the vulva initiated by high-risk oncogenic types of human papillomavirus (primarily HPV types 16 and 18)

Vulvar cancer is an uncommon gynecologic malignancy affecting female external genitalia, characteristically manifesting as persistent pruritus, pain, ulceration, or exophytic masses on the labia majora, labia minora, or clitoris Pathophysiologically, persistent mucosal infection with oncogenic HPV promotes cellular transformation through viral oncoproteins that inactivate host tumor suppressor proteins, driving progression from high-grade squamous intraepithelial lesions (vulvar intraepithelial ...

Pathophysiologically, persistent mucosal infection with oncogenic HPV promotes cellular transformation through viral oncoproteins that inactivate host tumor suppressor proteins, driving progression from high-grade squamous intraepithelial lesions (vulvar intraepithelial neoplasia) to invasive squamous cell carcinoma

Vaccination elicits neutralizing antibody responses prior to viral exposure, interrupting initial viral entry and thereby halting the oncogenic cascade leading to HPV-associated vulvar dysplasia and malignancy

Vaccination elicits neutralizing antibody responses prior to viral exposure, interrupting initial viral entry and thereby halting the oncogenic cascade leading to HPV-associated vulvar dysplasia and malignancy